GC녹십자웰빙 and 365mc sign MOU on next-generation fat-dissolving injection
In short
GC녹십자웰빙, an affiliate of GC녹십자, has signed a business agreement with 365mc covering a next-generation localized fat-dissolving injection. The two companies will pursue domestic clinical trials and commercialization of the candidate RZL-012, which GC녹십자웰빙 licensed exclusively for Korea from US-based Raziel Therapeutics. No financial terms or schedule were disclosed in the reports.
Read the full story 1 min read
GC녹십자웰빙, an affiliate of GC녹십자, has signed a business agreement with 365mc covering a next-generation localized fat-dissolving injection, according to Chosun Ilbo. The report said the two companies will pursue domestic clinical trials and commercialisation of the candidate substance RZL-012. GC녹십자웰빙 previously secured exclusive Korean development and commercialisation rights to RZL-012 from US-based Raziel Therapeutics, the outlet said. [ 2 ]
Korea Economic Daily framed the tie-up as cooperation between the two companies in the obesity management business, focused on the fat-dissolving injection drug. Newsis described the agreement as strengthening the commercialisation base. Neither report included financial terms, a signing location or a schedule, and none of the three documents carried executive quotes. [ 1 , 3 ]
Why it matters
The agreement moves a fat-dissolving injectable candidate toward Korean clinical trials and commercialisation under a domestic licence held by one of the two partners. Because the documents give no deal value, timeline or regulatory status, the practical effect on the companies’ businesses cannot be judged from the coverage. The reports are business-page announcements and do not assess the drug’s prospects.
Key facts
- GC녹십자웰빙, a GC녹십자 affiliate, signed a business agreement with 365mc, according to the companies’ announcement reported by Chosun Ilbo. [ 2 ]
- The agreement covers commercialisation of a next-generation localized fat-dissolving injection. [ 2 ]
- The two sides will pursue domestic clinical trials and commercialisation of the candidate substance RZL-012. [ 2 ]
- GC녹십자웰빙 previously secured exclusive Korean development and commercialisation rights to RZL-012 from US-based Raziel Therapeutics. [ 2 ]
- Korea Economic Daily described the tie-up as cooperation in the obesity management business. [ 1 ]
- Newsis framed the agreement as strengthening the commercialisation base. [ 3 ]
Confirmed by several sources
Still unclear
- Whether RZL-012 is the sole subject of the agreement and its exact development stage. Only Chosun Ilbo names the candidate substance; the other two documents refer to a fat-dissolving injection and obesity management without naming it.
- The value, duration and any exclusivity terms of the agreement. No document states financial or contractual terms.
- Where and when the agreement was signed. The documents give publication times only and no signing location or date.
- Whether clinical trials have already started or been scheduled. Chosun Ilbo says the two companies will pursue domestic clinical trials, without giving a start date.
What local media are saying
Timeline, local time
- Korea Economic Daily publishes a report describing cooperation between GC녹십자웰빙 and 365mc in the obesity management business and the fat-dissolving injection drug. [ 1 ]
- Chosun Ilbo reports that GC녹십자웰빙 signed an MOU with 365mc for commercialisation of the next-generation fat-dissolving injection, including domestic clinical trials of RZL-012. [ 2 ]
- Newsis publishes its report on the agreement, describing it as strengthening the commercialisation base. [ 3 ]